-- ============================================================================
-- SURGERY 3 MCQ BATCH 47: Endocrine Surgery Additional Topics (Questions 2761-2820)
-- Topic: Parathyroid, Adrenal, Thyroid Cancer, MEN Syndromes
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Parathyroid Surgery (1-20)
('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Primary hyperparathyroidism is most commonly caused by:',
'Parathyroid carcinoma', 'Single parathyroid adenoma (80-85% of cases)', 'Four-gland hyperplasia', 'Secondary hyperplasia', 'Parathyroid cyst',
'B', 'Primary hyperparathyroidism etiology: (1) Single adenoma: 80-85% (most common). (2) Four-gland hyperplasia: 10-15% (often familial/MEN). (3) Double adenoma: 2-5%. (4) Parathyroid carcinoma: less than 1% (suspect if PTH greater than 10x normal, palpable mass, very high calcium). Sporadic adenoma: most common cause of hypercalcemia in outpatients. Presentation: often asymptomatic (discovered incidentally), or stones, bones, groans, psychiatric overtones. Reference: Wilhelm SM. JAMA Surg. 2016.',
'easy', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'The biochemical hallmark of primary hyperparathyroidism is:',
'Low calcium, low PTH', 'Elevated calcium with inappropriately normal or elevated PTH', 'Low PTH with high calcium', 'Normal calcium and PTH', 'High phosphorus',
'B', 'Primary hyperparathyroidism biochemistry: (1) Hypercalcemia. (2) PTH elevated or inappropriately normal (should be suppressed if calcium high). (3) Hypophosphatemia (PTH causes phosphate wasting). (4) Elevated urinary calcium. (5) Elevated 1,25-vitamin D. Differentiate from: FHH (familial hypocalciuric hypercalcemia - low urinary calcium), malignancy-associated (PTH suppressed, PTHrP elevated), vitamin D toxicity (PTH suppressed). Reference: Bilezikian JP. J Clin Endocrinol Metab. 2014.',
'easy', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Preoperative localization for parathyroidectomy typically includes:',
'CT only', 'Sestamibi scan and/or neck ultrasound to identify enlarged gland(s)', 'MRI only', 'No localization needed', 'PET scan',
'B', 'Parathyroid localization: (1) Sestamibi scan (Tc-99m): taken up by hyperfunctioning parathyroid tissue, sensitivity 70-90% for adenoma. (2) Neck ultrasound: operator-dependent, 70-80% sensitivity, also evaluates thyroid. (3) 4D-CT: if above negative or discordant, useful for ectopic glands. (4) SPECT-CT: improved anatomic correlation. Localization enables focused/minimally invasive parathyroidectomy. If negative localization: bilateral exploration still curative. Reference: Cheung K. Ann Surg. 2012.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Intraoperative PTH monitoring is used during parathyroidectomy to:',
'Measure calcium', 'Confirm adequate resection by demonstrating greater than 50% PTH drop from baseline within 10 minutes after gland removal', 'Check blood type', 'Monitor heart rate', 'Assess kidney function',
'B', 'Intraoperative PTH (ioPTH): Miami criteria - PTH drops greater than 50% from highest pre-incision or pre-excision level, 10 minutes after gland removal. Predicts cure (97-98% accuracy). Enables focused parathyroidectomy (single gland removal if criteria met, no need to explore all four). If PTH does not drop: explore for additional abnormal glands (multigland disease, missed adenoma). Half-life of PTH: 3-5 minutes. Reference: Carneiro DM. Surgery. 2003.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Hungry bone syndrome after parathyroidectomy presents with:',
'Hypercalcemia', 'Hypocalcemia due to rapid calcium and phosphate uptake by bones that were previously PTH-depleted', 'Hyperkalemia', 'Metabolic acidosis', 'Hypertension',
'B', 'Hungry bone syndrome: (1) Severe, prolonged hypocalcemia post-parathyroidectomy. (2) Mechanism: bones rapidly take up calcium and phosphate for remineralization (were in high-turnover state from PTH). (3) Risk factors: older age, larger adenoma, higher preop calcium, bone disease (osteitis fibrosa cystica). (4) Presentation: hypocalcemia, hypophosphatemia, hypomagnesemia. (5) Treatment: aggressive calcium and vitamin D supplementation, may need IV calcium. (6) Can last weeks to months. Reference: Witteveen JE. Eur J Endocrinol. 2013.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Secondary hyperparathyroidism is caused by:',
'Parathyroid adenoma', 'Chronic kidney disease (most common) causing chronic hypocalcemia and phosphate retention, stimulating all parathyroid glands', 'Parathyroid carcinoma', 'MEN syndrome', 'Thyroid cancer',
'B', 'Secondary hyperparathyroidism: (1) Cause: chronic hypocalcemia stimulates parathyroid hyperplasia. (2) Most common: chronic kidney disease (decreased 1,25 vitamin D, phosphate retention, hypocalcemia). (3) Other causes: vitamin D deficiency, malabsorption. (4) Labs: elevated PTH, normal or low calcium (vs primary which has high calcium). (5) All four glands enlarged. (6) Treatment: address underlying cause, phosphate binders, vitamin D, calcimimetics (cinacalcet), surgery if refractory (subtotal parathyroidectomy). Reference: Cunningham J. Kidney Int. 2011.',
'medium', 'knowledge'),

-- Adrenal Surgery (21-40)
('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Pheochromocytoma is a catecholamine-secreting tumor arising from:',
'Adrenal cortex', 'Adrenal medulla chromaffin cells', 'Kidney', 'Pancreas', 'Thyroid',
'B', 'Pheochromocytoma: tumor of chromaffin cells. Location: adrenal medulla (90%), extra-adrenal (paraganglioma - 10%). Rule of 10s (historical): 10% bilateral, 10% extra-adrenal, 10% malignant, 10% familial. Revised: 30-40% have germline mutation (VHL, MEN2, SDH, NF1). Secretes: epinephrine, norepinephrine (dopamine rarely). Presentation: paroxysmal hypertension, headache, sweating, palpitations, anxiety. Diagnosis: plasma/urine metanephrines. Reference: Lenders JW. Lancet. 2005.',
'easy', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'The classic triad of pheochromocytoma symptoms is:',
'Fever, rash, arthralgia', 'Episodic headache, sweating, and palpitations (often with hypertension)', 'Polyuria, polydipsia, polyphagia', 'Weight gain, fatigue, cold intolerance', 'Nausea, vomiting, diarrhea',
'B', 'Pheochromocytoma triad: headache, diaphoresis (sweating), palpitations. Also: hypertension (sustained or paroxysmal - 90%), anxiety, tremor, pallor, hyperglycemia. Symptoms are paroxysmal (lasting minutes to hours). Triggers: exercise, stress, surgery, anesthesia, certain foods/medications. Can be asymptomatic (incidentaloma). Hypertensive crisis can be fatal if unrecognized. Reference: Lenders JW. Lancet. 2005.',
'easy', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'The biochemical test with highest sensitivity for pheochromocytoma is:',
'24-hour urinary VMA', 'Plasma or 24-hour urinary fractionated metanephrines', 'Serum catecholamines', 'Random urine catecholamines', 'Cortisol level',
'B', 'Pheochromocytoma diagnosis: (1) Plasma free metanephrines: highest sensitivity (96-99%), preferred initial test, measure fasting and supine. (2) 24-hour urinary fractionated metanephrines and catecholamines: also high sensitivity, useful confirmation. (3) False positives: medications, stress, posture, foods. If positive: imaging (CT or MRI) to localize. If negative imaging: consider MIBG scan or PET. Genetic testing recommended for all pheo patients. Reference: Lenders JW. J Clin Endocrinol Metab. 2014.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Preoperative alpha-blockade for pheochromocytoma is essential to:',
'Improve tumor visualization', 'Prevent intraoperative hypertensive crisis from catecholamine surge during tumor manipulation', 'Reduce tumor size', 'Enhance anesthesia', 'Prevent infection',
'B', 'Alpha-blockade for pheo: ESSENTIAL before surgery. Purpose: prevent hypertensive crisis during induction/tumor manipulation. Regimen: (1) Phenoxybenzamine (irreversible alpha-blocker) or doxazosin/prazosin started 7-14 days preoperatively. (2) High sodium diet and fluids (catecholamines cause volume contraction). (3) Beta-blocker added AFTER adequate alpha-blockade (never before - unopposed alpha causes severe hypertension). (4) Goal: BP less than 130/80 seated, orthostatic hypotension confirms adequate blockade. Reference: Pacak K. Endocr Rev. 2007.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Cushing syndrome is caused by:',
'Low cortisol', 'Chronic excess cortisol from any source (exogenous, pituitary, adrenal, or ectopic ACTH)', 'Low ACTH', 'Catecholamine excess', 'Aldosterone deficiency',
'B', 'Cushing syndrome: chronic hypercortisolism. Causes: (1) Exogenous steroids (most common overall). (2) ACTH-dependent (80%): Cushing disease (pituitary adenoma - 70%), ectopic ACTH (lung cancer, carcinoid). (3) ACTH-independent (20%): adrenal adenoma, adrenal carcinoma, bilateral nodular hyperplasia. Features: central obesity, moon facies, buffalo hump, striae, hypertension, diabetes, osteoporosis, hirsutism, proximal weakness, psychiatric changes. Reference: Nieman LK. Lancet. 2015.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Primary aldosteronism (Conn syndrome) presents with:',
'Hypotension', 'Hypertension with hypokalemia (though many are normokalemic) and metabolic alkalosis', 'Hypercalcemia', 'Weight loss', 'Hypoglycemia',
'B', 'Primary aldosteronism: autonomous aldosterone production. Causes: (1) Aldosterone-producing adenoma (APA/Conn syndrome - 35%), (2) Bilateral adrenal hyperplasia (BAH - 60%). Presentation: hypertension (often resistant), hypokalemia (only 30% now - milder cases detected), metabolic alkalosis, muscle weakness. Screening: aldosterone/renin ratio (ARR). Confirmation: salt loading suppression test. Subtype differentiation: CT + adrenal vein sampling. Treatment: APA - adrenalectomy, BAH - mineralocorticoid receptor antagonists (spironolactone, eplerenone). Reference: Funder JW. J Clin Endocrinol Metab. 2016.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Adrenal incidentaloma workup should evaluate for:',
'Size only', 'Functional status (cortisol, catecholamines, aldosterone if hypertensive) and malignancy potential (size, imaging characteristics)', 'No workup needed', 'Biopsy all lesions', 'Only cortisol',
'B', 'Adrenal incidentaloma evaluation: (1) Function: All need biochemical workup - overnight dexamethasone suppression test (Cushing), plasma/urine metanephrines (pheo), aldosterone/renin if hypertensive/hypokalemic. (2) Malignancy risk: Size (greater than 4 cm more concerning), imaging features (irregular borders, heterogeneity, high HU on unenhanced CT greater than 10, slow washout). (3) Management: functional tumors - surgery. Non-functional: less than 4 cm and benign features - follow, greater than 4 cm or concerning features - consider surgery. Biopsy: only if suspected metastasis and will change management. Reference: Fassnacht M. Eur J Endocrinol. 2016.',
'medium', 'knowledge'),

-- Thyroid Cancer (41-55)
('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'The most common type of thyroid cancer is:',
'Anaplastic', 'Papillary thyroid carcinoma (80-85% of thyroid cancers)', 'Medullary', 'Follicular', 'Lymphoma',
'B', 'Thyroid cancer types: (1) Papillary: 80-85%, best prognosis (greater than 98% 10-year survival), lymph node spread common, associated with radiation exposure. (2) Follicular: 10-15%, hematogenous spread (bone, lung), better prognosis. (3) Medullary (MTC): 5%, C-cells, calcitonin, familial (MEN2) or sporadic, moderate prognosis. (4) Anaplastic: less than 2%, worst prognosis (median survival 6 months), rapidly fatal. (5) Thyroid lymphoma: rare, often Hashimoto background. Reference: Cabanillas ME. Lancet. 2016.',
'easy', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Papillary thyroid carcinoma is characterized histologically by:',
'Follicular pattern only', 'Orphan Annie eye nuclei (clear nuclei), nuclear grooves, and psammoma bodies', 'Giant cells', 'Necrosis', 'Amyloid deposits',
'B', 'PTC histology: (1) Orphan Annie eye nuclei: clear, empty-appearing nuclei with ground-glass appearance. (2) Nuclear grooves. (3) Nuclear inclusions (pseudoinclusions). (4) Psammoma bodies (calcified laminated concretions - not specific but characteristic). (5) Papillary architecture (not required for diagnosis). Variants: classic, follicular variant, tall cell (more aggressive), encapsulated. Diagnosis is based on nuclear features, not architecture. Reference: LiVolsi VA. Mod Pathol. 2011.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Medullary thyroid carcinoma (MTC) arises from:',
'Follicular cells', 'Parafollicular C cells that produce calcitonin', 'Parathyroid cells', 'Lymphocytes', 'Stromal cells',
'B', 'MTC origin: parafollicular C cells (neural crest origin). Marker: calcitonin (tumor marker for surveillance). Also produces: CEA. Forms: (1) Sporadic (75%) - older, unilateral. (2) Hereditary (25%) - MEN2A, MEN2B, familial MTC - younger, bilateral, multicentric. Histology: amyloid deposits (calcitonin). RET mutation: found in all MEN2 and many sporadic cases. Treatment: total thyroidectomy + central neck dissection. Does not respond to RAI. Prognosis: 10-year survival 65-85%. Reference: Wells SA. J Clin Endocrinol Metab. 2015.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Anaplastic thyroid carcinoma is characterized by:',
'Excellent prognosis', 'Rapidly progressive, undifferentiated tumor with very poor prognosis (median survival 3-6 months)', 'Response to radioactive iodine', 'Slow growth', 'Only affects young patients',
'B', 'Anaplastic thyroid carcinoma: most aggressive thyroid malignancy. Features: (1) Undifferentiated (dedifferentiated from well-differentiated cancer in some cases). (2) Elderly patients (60-70 years). (3) Rapidly enlarging neck mass. (4) Local invasion (trachea, esophagus, vessels). (5) Distant metastases common. Diagnosis: biopsy showing undifferentiated cells. Does not take up iodine. Treatment: multimodal (surgery if resectable, radiation, chemotherapy), often palliative. BRAF/MEK inhibitors showing promise. Median survival: 3-6 months. Reference: Smallridge RC. Thyroid. 2012.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Radioactive iodine (I-131) therapy after thyroidectomy is used for:',
'All thyroid cancers', 'Differentiated thyroid cancer (papillary/follicular) for remnant ablation and treatment of iodine-avid metastases', 'Medullary thyroid cancer', 'Anaplastic cancer', 'Benign goiter only',
'B', 'Radioactive iodine (RAI) therapy: (1) Indication: differentiated thyroid cancer (DTC - papillary, follicular) with intermediate or high risk features. (2) Purpose: ablate remnant thyroid tissue, treat iodine-avid metastases. (3) Requires TSH stimulation (TSH greater than 30): thyroid hormone withdrawal or recombinant TSH (Thyrogen). (4) Low-iodine diet before treatment. (5) NOT effective for: MTC, anaplastic (do not take up iodine). Post-ablation: whole-body scan to detect metastases. Reference: Haugen BR. Thyroid. 2016 (ATA Guidelines).',
'medium', 'knowledge'),

-- MEN Syndromes (56-60)
('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Multiple Endocrine Neoplasia type 1 (MEN1) includes:',
'Thyroid cancer, pheochromocytoma, hyperparathyroidism', 'Primary hyperparathyroidism, pituitary tumors, and pancreatic neuroendocrine tumors (the 3 Ps)', 'Medullary thyroid cancer and pheochromocytoma', 'Only thyroid cancer', 'Adrenocortical tumors only',
'B', 'MEN1 (Wermer syndrome): 3 Ps: (1) Parathyroid: primary hyperparathyroidism (90-100%, usually 4-gland hyperplasia, earliest manifestation). (2) Pancreas: pancreatic NETs (gastrinoma most common functional - ZES, insulinoma). (3) Pituitary: adenomas (prolactinoma most common). Gene: MEN1 (menin) tumor suppressor on 11q13. Autosomal dominant. Other: adrenal cortical tumors, carcinoid, lipomas. Reference: Thakker RV. N Engl J Med. 2012.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'Multiple Endocrine Neoplasia type 2A (MEN2A) includes:',
'Pituitary adenoma, hyperparathyroidism, pancreatic NETs', 'Medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism', 'Only thyroid cancer', 'Parathyroid adenoma only', 'Insulinoma and gastrinoma',
'B', 'MEN2A (Sipple syndrome): (1) Medullary thyroid carcinoma (MTC): 100% penetrance, often bilateral/multicentric. (2) Pheochromocytoma: 50%, often bilateral. (3) Primary hyperparathyroidism: 20-30%. Gene: RET proto-oncogene (gain-of-function mutation), chromosome 10. Autosomal dominant. Prophylactic thyroidectomy based on RET mutation risk stratification. Screen pheo BEFORE thyroid surgery (dangerous if missed). Reference: Wells SA. N Engl J Med. 2013.',
'medium', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'MEN2B differs from MEN2A by:',
'Having parathyroid disease', 'Including mucosal neuromas, marfanoid habitus, and more aggressive MTC, but NOT hyperparathyroidism', 'Having pituitary tumors', 'Being autosomal recessive', 'Only affecting females',
'B', 'MEN2B features: (1) Medullary thyroid carcinoma: earliest, most aggressive (prophylactic thyroidectomy in infancy). (2) Pheochromocytoma: 50%. (3) Mucosal neuromas: lips, tongue, eyelids (bumpy lips). (4) Intestinal ganglioneuromatosis. (5) Marfanoid habitus (without lens or cardiac abnormalities). (6) NO hyperparathyroidism (unlike MEN2A). RET mutation: usually M918T. Most aggressive phenotype - MTC can occur in infancy. Reference: Brandi ML. J Clin Endocrinol Metab. 2001.',
'hard', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'RET proto-oncogene testing in MEN2 kindreds allows for:',
'No clinical utility', 'Prophylactic thyroidectomy based on mutation-specific risk stratification before MTC develops', 'Treatment of established cancer only', 'Avoiding all screening', 'Dietary recommendations only',
'B', 'RET testing and prophylactic surgery: (1) RET mutations correlate with MTC aggressiveness. (2) Risk stratification: Highest risk (M918T/MEN2B): thyroidectomy in first year of life. High risk: thyroidectomy by age 5. Moderate risk: thyroidectomy can be individualized. (3) Genetic testing of at-risk family members enables prophylactic surgery before MTC develops. (4) Lifelong screening for pheochromocytoma. (5) Revolutionized management of hereditary MTC. Reference: Wells SA. Thyroid. 2015 (ATA MTC Guidelines).',
'hard', 'knowledge'),

('c0000062-0000-0000-0000-000000000062', 'a0000003-0000-0000-0000-000000000003',
'In a patient with MEN2 and pheochromocytoma requiring thyroidectomy for MTC, the surgical priority is:',
'Thyroidectomy first', 'Adrenalectomy for pheochromocytoma first to prevent life-threatening hypertensive crisis during subsequent surgery', 'Simultaneous procedures always', 'Neither requires surgery', 'Parathyroidectomy first',
'B', 'MEN2 surgical sequencing: PHEOCHROMOCYTOMA FIRST. Rationale: undiagnosed/untreated pheo during thyroid surgery can cause hypertensive crisis, arrhythmias, death from catecholamine surge during induction/manipulation. Always: screen for pheochromocytoma (plasma metanephrines) before any surgery in MEN2 patient. If pheo present: alpha-blockade, adrenalectomy first, then thyroidectomy. Cortical-sparing adrenalectomy considered in bilateral cases to preserve adrenal function. Reference: Duh QY. World J Surg. 2015.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 47 (Endocrine Surgery Additional): 60 questions inserted' as status;
